The direct oral anticoagulants market is likely to register a CAGR of 7.5% during the forecast period, and is anticipated to reach a market share of US$ 71.78 Bn in 2032, from US$ 24.26 Bn in 2021, due to growing approval from the FDA and CE mark for the direct oral anticoagulants.
| Attributes | Details |
|---|---|
| Direct Oral Anticoagulants Market CAGR | 7.5% |
| Direct Oral Anticoagulants Market Size (2032) | US$ 71.78 Billion |
| Direct Oral Anticoagulants Market Size (2021) | US$ 24.26 Billion |
The direct oral anticoagulants market share will grow due to rapid uptake and predicted usage in the huge patient population affected by thrombosis. The demand for direct oral anticoagulants will benefit from improvements in the quality of anticoagulant therapy by providing an alternative to warfarin.
Direct oral anticoagulants provide consistent inter-individual efficacy, uniform dose, and no monitoring, implying that the global direct oral anticoagulants market has a lot of room to grow in the near future. Sales of direct oral anticoagulants will increase as the incidence of Venous Thromboembolism among cancer patients continues to rise.
Traditional anticoagulants need monthly blood tests, dietary restrictions, and close monitoring to uncontrolled bleeding, therefore demand for direct oral anticoagulants is high. Furthermore, sales of direct oral anticoagulants are high, as they are very effective, need less monitoring, and minimize the risk of brain hemorrhage when used to prevent stroke.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The demand for direct oral anticoagulants as a first-line treatment for venous thromboembolism and atrial fibrillation is projected to drive the global direct oral anticoagulants market. In the near future, the direct oral anticoagulants market will be boosted by the FDA's growing approval and the CE mark for direct oral anticoagulants.
In the forecast period, rising incidences of thrombosis, which is a leading cause of morbidity and mortality in various areas of the world, are likely to fuel the sales of direct oral anticoagulants.
However, there are a number of factors that may limit the sales of direct oral anticoagulants, including their higher cost as compared to warfarin and their shorter acting dosage, which necessitates strict adherence to dosing schedules.
Furthermore, rigorous drug development rules are expected to limit the demand for direct oral anticoagulants.
Principal Consultant
Due to the rapid uptake of novel direct oral anticoagulants and the rise in atrial fibrillation patients treated with anticoagulants, North America is likely to account for a significant direct oral anticoagulants market share. The demand for direct oral anticoagulants in North America is predicted to grow as the number of operations and the frequency of chronic disease rises.
Due to increasing permission for drug development, Europe is predicted to provide the second highest direct oral anticoagulants market share worldwide, with significant growth. The sales of direct oral anticoagulants is projected to be driven by a growing focus on the development of innovative coagulation therapies.
The Asia Pacific market is primarily driven by factors, such as rising cancer incidence and venous thrombosis risk. The demand for direct oral anticoagulants is likely to be driven by rising awareness of new therapies and increased usage due to a large patient pool in emerging economies such as India and ASEAN countries.
Due to advancements in novel therapies and the expanding presence of important manufacturers, China is projected to see substantial growth in sales of direct oral anticoagulants. Due to a lack of awareness and limited acceptance due to the high price of direct oral anticoagulants, the market in Latin America, the Middle East and Africa is likely to slow down in sales of direct oral anticoagulants.
Some of the key players present in the global direct oral anticoagulants market are Pfizer Inc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb Co, Pab Organics Private Limited, Daiichi Sankyo Company, Limited, among others, holding a substantial direct oral anticoagulants market share.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth rate | CAGR of 7.5% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD billion, volume in kilotons and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors and trends, Pricing Analysis |
| Segments covered | Drug type, distribution channel, region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Pfizer Inc; Teva Pharmaceutical Industries Ltd; Boehringer Ingelheim Pharmaceuticals, Inc; Janssen Pharmaceuticals, Inc; Bayer AG; Bristol-Myers Squibb Co; Pab Organics Private Limited; Daiichi Sankyo Company; Limited; among others |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The direct oral anticoagulants market is anticipated to register a CAGR of 7.5% during the forecast period.
The direct oral anticoagulants market share is anticipated to reach US$ 71.78 Bn in 2032.
Demand for direct oral anticoagulants is likely to rise, due to growing approval from the FDA and CE mark for the direct oral anticoagulants.
Explore Healthcare Insights
View Reports
Direct Oral Anticoagulants Market
